Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 4/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28937142 | 0.81 | MEN1 (0.60) | RXFP1MEN1KMT2ACCNA2CDK2 | |
| SCHEMBL20177033 | 0.80 | MEN1 (0.47) | RXFP1MEN1KMT2AGRM5TDP1 | |
| SCHEMBL2397764 | 0.78 | RXFP1 (0.71) | RXFP1MEN1KMT2AGRM5LMNA | |
| SCHEMBL28808130 | 0.78 | CHRNB2 (0.60) | RXFP1MEN1KMT2AGRM5LMNA | |
| SCHEMBL28937136 | 0.78 | F2 (0.53) | RXFP1MEN1KMT2ACCNA2CDK2 | |
| SCHEMBL16899070 | 0.78 | SMN1; SMN2 (0.64) | RXFP1MEN1KMT2ACCNA2CDK2 | |
| SCHEMBL3631785 | 0.74 | MEN1 (0.50) | MEN1KMT2AGRM5LMNATP53 | |
| SCHEMBL16594642 | 0.74 | RAB9A (0.83) | MEN1KMT2ALMNATDP1TP53 | |
| SCHEMBL15527872 | 0.73 | TP53 (0.57) | MEN1KMT2AHDAC1TDP1TP53 | |
| SCHEMBL28808121 | 0.73 | RXFP1 (0.78) | RXFP1MEN1KMT2AGRM5TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3897855-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2019-11-21 | — | — | US | disclosed |
| WO-2018092047-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, ABL1, CNKSR1 | RXFP1 3123/4885MEN1 3821/4885KMT2A 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.